AN17: R&d- medical: biomedical (commercialized)
Figures are FPDS award actions reporting this code.
Research and development code
Inactive
Overview
- FY2026 obligations
- $105.27M
- $105,274,409awarded under AN17
- FY2026 awards
- 1
- awards with an action under this code
- Open notices
- 0
- open SAM.gov notices classified under AN17
Obligations by fiscal year of action
- FY2026: $105,274,409
- FY2025: $8,286,638
- FY2024: $90,590,543
- FY2023: $52,036,639
- FY2022: $88,448,071
Total across 5 fiscal years: $344,636,301
Source: FPDS award actions reporting this PSC. Obligations are the sum of the obligation on each action (modifications included). Department of Defense actions appear about 90 days after they are signed.
Definition
- Official name
- R&D- MEDICAL: BIOMEDICAL (COMMERCIALIZED)
- Status
- Inactive since October 29, 2020
Top buying agencies
FY2024–FY2026 · awarding sub-tier agencies
| Rank | Agency | Obligated | |
|---|---|---|---|
| 1 | Administration For Strategic Preparedness And Response | $204,760,551 | 100% |
Top vendors
FY2024–FY2026
| Rank | Vendor | Obligated | ||
|---|---|---|---|---|
| 1 | PHLOW CORP. | $204,760,551 | 1 | 100% |